Hypertrophic cardiomyopathy secondary prevention

Revision as of 21:38, 7 January 2020 by Soroush Seifirad (talk | contribs)
Jump to navigation Jump to search

Hypertrophic Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypertrophic Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertrophic cardiomyopathy secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertrophic cardiomyopathy secondary prevention

CDC on Hypertrophic cardiomyopathy secondary prevention

Hypertrophic cardiomyopathy secondary prevention in the news

Blogs on Hypertrophic cardiomyopathy secondary prevention

Directions to Hospitals Treating Hypertrophic cardiomyopathy

Risk calculators and risk factors for Hypertrophic cardiomyopathy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening, [strategy 2], and [strategy 3].

Secondary Prevention

Effective measures for the secondary prevention of hypertrophic cardiomyopathy include:

  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]

References

Template:WH Template:WS